000112120 001__ 112120
000112120 005__ 20240319080957.0
000112120 0247_ $$2doi$$a10.3201/eid2803.212027
000112120 0248_ $$2sideral$$a128090
000112120 037__ $$aART-2022-128090
000112120 041__ $$aeng
000112120 100__ $$aCura-Bilbao, A. del
000112120 245__ $$aEffectiveness of 3 COVID-19 vaccines in preventing SARS-CoV-2 infections, January–May 2021, Aragon, Spain
000112120 260__ $$c2022
000112120 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112120 5203_ $$aReducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission is a worldwide challenge; widespread vaccination could be one strategy for control. We conducted a prospective, population-based cohort study of 964, 258 residents of Aragon, Spain, during December 2020–May 2021. We used the Cox proportional-hazards model with vaccination status as the exposure condition to estimate the effectiveness of 3 coronavirus disease vaccines in preventing SARS-CoV-2 infection. Pfizer-BioNTech had 20.8% (95% CI 11.6%–29.0%) vaccine effectiveness (VE) against infection after 1 dose and 70.0% (95% CI 65.3%–74.1%) after 2 doses, Moderna had 52.8% (95% CI 30.7%–67.8%) VE after 1 dose and 70.3% (95% CI 52.2%–81.5%) after 2 doses, and Oxford-AstraZeneca had 40.3% (95% CI 31.8%–47.7%) VE after 1 dose. All estimates were lower than those from previous studies. Results imply that, although high vaccination coverage remains critical to protect people from disease, it will be difficult to effectively minimize transmission opportunities.
000112120 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112120 590__ $$a11.8$$b2022
000112120 592__ $$a3.05$$b2022
000112120 591__ $$aINFECTIOUS DISEASES$$b10 / 96 = 0.104$$c2022$$dQ1$$eT1
000112120 593__ $$aEpidemiology$$c2022$$dQ1
000112120 591__ $$aIMMUNOLOGY$$b16 / 161 = 0.099$$c2022$$dQ1$$eT1
000112120 593__ $$aMicrobiology (medical)$$c2022$$dQ1
000112120 593__ $$aInfectious Diseases$$c2022$$dQ1
000112120 594__ $$a15.6$$b2022
000112120 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112120 700__ $$0(orcid)0000-0002-4528-1921$$aLópez-Mendoza, H.
000112120 700__ $$aChaure-Pardos, A.$$uUniversidad de Zaragoza
000112120 700__ $$aVergara-Ugarriza, A.
000112120 700__ $$aGuimbao-Bescós, J.
000112120 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000112120 773__ $$g28, 3 (2022), 591-598$$pEmerg. infect. dis.$$tEmerging Infectious Diseases$$x1080-6040
000112120 8564_ $$s1204158$$uhttps://zaguan.unizar.es/record/112120/files/texto_completo.pdf$$yVersión publicada
000112120 8564_ $$s2900584$$uhttps://zaguan.unizar.es/record/112120/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112120 909CO $$ooai:zaguan.unizar.es:112120$$particulos$$pdriver
000112120 951__ $$a2024-03-18-13:47:19
000112120 980__ $$aARTICLE